Zavabresib

N/A

Report date: 2026/01/28 17:56:31
NME

Base Information

Drug NameZavabresib
Drug Alias Namean orally active, small molecule inhibitor of bromodomain (BRD) and extra terminal domain (BET) family proteinsPLX-2853OPN-2853
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain-containing protein 4 inhibitors
TargetsBromodomain-containing protein 4
Therapy Area/IndicationsUveal melanomaSolid tumoursMyelodysplastic Syndromes +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPlexxikon Inc
China Registration ClassN/A

Develop Information

Active CompaniesOpna Bio LLCOpna Bio SA
Inactive CompaniesAlliance For Clinical Trials In Oncology
Active IndicationsUveal melanomaSolid tumoursMyelodysplastic Syndromes +[9] 
Inactive IndicationsProstatic Neoplasms, Castration-ResistantGenital Neoplasms, FemaleCarcinoma, Ovarian Epithelial +[4] 

Other Information

ATC CodeN/A
Related LinksN/A